Literature DB >> 25150641

Human papillomavirus prevalence in invasive penile cancer and association with clinical outcome.

Rosa S Djajadiningrat1, Ekaterina S Jordanova2, Bin K Kroon1, Erik van Werkhoven3, Jeroen de Jong4, Divera T M Pronk5, Peter J F Snijders5, Simon Horenblas6, Daniëlle A M Heideman5.   

Abstract

PURPOSE: The incidence of penile cancer is increasing, and is suggested to be explained by changes in sexual practice and increased exposure of men to sexually transmitted high risk human papillomavirus infection. In penile cancers from a Dutch population treated in 1963 to 2001 we found a high risk human papillomavirus prevalence of about 30%. In this study we assessed the prevalence of high risk human papillomavirus-DNA in a more recent, contemporary penile cancer cohort and its association with patient survival.
MATERIALS AND METHODS: High risk human papillomavirus-DNA presence was assessed by GP5+6+ polymerase chain reaction in 212 formalin fixed, paraffin embedded invasive penile tumor specimens of patients treated between 2001 and 2009. The 5-year disease specific survival was calculated using the Kaplan-Meier method with the log rank test and Cox regression.
RESULTS: High risk human papillomavirus-DNA was detected in a subset of penile cancer cases (25%, 95% CI 19-31). HPV16 was the predominant type, representing 79% (42 of 53) of all high risk human papillomavirus infections. The 5-year disease specific survival in the high risk human papillomavirus negative group and the high risk human papillomavirus positive group was 82% and 96%, respectively (log rank test p=0.016). Adjusted for stage, grade, lymphovascular invasion and age, human papillomavirus status was still prognostic for disease specific survival (p=0.030) with a hazard ratio of 0.2 (95% CI 0.1-0.9).
CONCLUSIONS: High risk human papillomavirus-DNA was observed in a quarter of penile cancer cases. No relevant increase in high risk human papillomavirus prevalence in recent decades was observed. The presence of high risk human papillomavirus-DNA in penile cancer confers a survival advantage.
Copyright © 2015 American Urological Association Education and Research, Inc. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  carcinoma; human papillomavirus 16; penile neoplasms; squamous cell; survival

Mesh:

Substances:

Year:  2014        PMID: 25150641     DOI: 10.1016/j.juro.2014.08.087

Source DB:  PubMed          Journal:  J Urol        ISSN: 0022-5347            Impact factor:   7.450


  21 in total

1.  Genital Human Papillomavirus Infection Progression to External Genital Lesions: The HIM Study.

Authors:  Staci L Sudenga; Donna J Ingles; Christine M Pierce Campbell; Hui-Yi Lin; William J Fulp; Jane L Messina; Mark H Stoler; Martha Abrahamsen; Luisa L Villa; Eduardo Lazcano-Ponce; Anna R Giuliano
Journal:  Eur Urol       Date:  2015-06-06       Impact factor: 20.096

2.  Comparison of the Natural History of Genital HPV Infection among Men by Country: Brazil, Mexico, and the United States.

Authors:  Staci L Sudenga; B Nelson Torres; Roberto Silva; Luisa L Villa; Eduardo Lazcano-Ponce; Martha Abrahamsen; Maria Luiza Baggio; Jorge Salmeron; Manuel Quiterio; Anna R Giuliano
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2017-04-26       Impact factor: 4.254

Review 3.  Current Management Strategy for Penile Cancer and Future Directions.

Authors:  Tanya B Dorff; Leslie K Ballas; Anne K Schuckman
Journal:  Curr Oncol Rep       Date:  2017-08       Impact factor: 5.075

4.  Country-specific HPV-related genital disease among men residing in Brazil, Mexico and The United States: The HIM study.

Authors:  Staci L Sudenga; B Nelson Torres; William J Fulp; Roberto Silva; Luisa L Villa; Eduardo Lazcano-Ponce; Donna J Ingles; Mark Stoler; Jane L Messina; Martha Abrahamsen; Maria Luiza Baggio; Jorge Salmeron; Manuel Quiterio; Anna R Giuliano
Journal:  Int J Cancer       Date:  2016-10-20       Impact factor: 7.396

5.  Prevalence of human papillomavirus and implication on survival in Chinese penile cancer.

Authors:  Chengbiao Chu; Keming Chen; Xingliang Tan; Jiangli Lu; Yuanzhong Yang; YiJun Zhang; Kai Yao; Yun Cao
Journal:  Virchows Arch       Date:  2020-05-19       Impact factor: 4.064

Review 6.  Immune-based therapies in penile cancer.

Authors:  Vidhu B Joshi; Philippe E Spiess; Andrea Necchi; Curtis A Pettaway; Jad Chahoud
Journal:  Nat Rev Urol       Date:  2022-07-18       Impact factor: 16.430

7.  Clinical Significance of p53 and p16(ink4a) Status in a Contemporary North American Penile Carcinoma Cohort.

Authors:  Kamran Zargar-Shoshtari; Philippe E Spiess; Anders E Berglund; Pranav Sharma; Julio M Powsang; Anna Giuliano; Anthony M Magliocco; Jasreman Dhillon
Journal:  Clin Genitourin Cancer       Date:  2015-12-23       Impact factor: 2.872

8.  Penile cancer: potential target for immunotherapy?

Authors:  Joren Vanthoor; Gigi Vos; Maarten Albersen
Journal:  World J Urol       Date:  2020-11-03       Impact factor: 4.226

Review 9.  Contemporary role of radiotherapy in the management of penile cancer.

Authors:  Martin Arthur Korzeniowski; Juanita Mary Crook
Journal:  Transl Androl Urol       Date:  2017-10

10.  Human Papillomavirus Type 16 Integration Analysis by Real-time PCR Assay in Associated Cancers.

Authors:  Mohammad Hadi Karbalaie Niya; Hossein Keyvani; Fahimeh Safarnezhad Tameshkel; Mostafa Salehi-Vaziri; Sedigheh Teaghinezhad-S; Farah Bokharaei Salim; Seyed Hamid Reza Monavari; Davod Javanmard
Journal:  Transl Oncol       Date:  2018-03-13       Impact factor: 4.243

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.